Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $27.43.
Several analysts have issued reports on the company. JMP Securities boosted their price objective on Exelixis from $27.00 to $29.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 7th. Truist Financial restated a “buy” rating and issued a $33.00 price target (up previously from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a research note on Wednesday, August 7th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, Stephens started coverage on Exelixis in a research report on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 target price for the company.
Check Out Our Latest Stock Analysis on Exelixis
Insider Activity at Exelixis
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in EXEL. Norges Bank bought a new stake in Exelixis during the 4th quarter worth about $73,449,000. LSV Asset Management lifted its holdings in shares of Exelixis by 107.7% in the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Exelixis by 948.3% during the first quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after buying an additional 2,220,150 shares during the period. Jupiter Asset Management Ltd. grew its holdings in shares of Exelixis by 148.2% during the first quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock worth $53,817,000 after buying an additional 1,354,062 shares in the last quarter. Finally, Swedbank AB acquired a new stake in Exelixis in the 1st quarter valued at approximately $22,455,000. 85.27% of the stock is owned by institutional investors.
Exelixis Stock Performance
Exelixis stock opened at $25.15 on Monday. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 39.30, a price-to-earnings-growth ratio of 0.50 and a beta of 0.54. Exelixis has a 1 year low of $18.64 and a 1 year high of $27.53. The firm’s 50 day moving average price is $24.31 and its two-hundred day moving average price is $22.99.
Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.44. The business had revenue of $637.18 million during the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. As a group, equities analysts predict that Exelixis will post 1.54 EPS for the current fiscal year.
About Exelixis
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Further Reading
- Five stocks we like better than Exelixis
- What is the Dow Jones Industrial Average (DJIA)?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.